Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma

Abstract Advanced esophageal squamous cell carcinoma (ESCC) patients exhibit a ~ 50% objective response rate (ORR) and median progression-free survival (mPFS) of just 5–7 months when undergoing first-line immune-chemotherapeutic treatment, underscoring pronounced unmet clinical need. We assessed the...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingfang Xu, Yu Pu, Yuzhu Jiang, Yingda Liu, Yan Feng, Xiaodong Zhao, Mengxia Li
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Esophageal squamous cell carcinoma
Anlotinib
ICIs
First-line treatment
Online Access:https://doi.org/10.1038/s41598-025-06625-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items